Do CRP rs1205 and IL6R rs2228145 variants change CRP levels and IL-6 signaling?

The claims that the CRP rs1205 and IL6R rs2228145 genetic variants are associated with differences in circulating C-reactive protein (CRP) levels, altered interleukin-6 (IL-6) signaling, and modified acute-phase CRP responses are strongly supported by scientific evidence.

Below is an assessment of the clinical, mechanistic, and practical implications of these genetic variations.

Clinical and effectiveness evidence

Large-scale clinical and epidemiological studies demonstrate that these two variants are robust genetic determinants of baseline and acute-phase inflammatory biomarkers:

• The CRP rs1205 variant: This single-nucleotide polymorphism (SNP) is a primary driver of baseline circulating CRP. Epidemiological cohorts show that carriers of the minor allele exhibit significantly lower baseline high-sensitivity CRP (hs-CRP) levels. For instance, in aging male cohorts, carriers of the minor allele present with roughly 20% lower baseline serum CRP than non-carriers. In clinical cohorts, such as untreated early rheumatoid arthritis patients, homozygous minor allele carriers present with baseline CRP values up to 50% lower than major-allele homozygotes.
• The IL6R rs2228145 variant: This variant (Asp358Ala) alters systemic IL-6 and CRP dynamics. Intriguingly, individuals carrying the Ala allele show paradoxically elevated circulating levels of both IL-6 and soluble IL-6 receptor (sIL-6R), yet they experience a lower risk of coronary heart disease, rheumatoid arthritis, and abdominal aortic aneurysm. This occurs because the systemic signaling profile is shifted away from localized, membrane-bound classical activation.

Mechanistic explanations

These genetic variants alter basic cellular and molecular pathways, changing how the body processes inflammatory signals:

• Receptor shedding dynamics: The IL6R rs2228145 variant is located in the extracellular stalk of the IL-6 receptor. The substitution increases susceptibility to proteolytic cleavage (shedding) by metalloproteases (such as ADAM10 and ADAM17).
• Classic vs. trans-signaling: Increased shedding reduces the density of membrane-bound IL-6R (mIL-6R) on hepatocytes and leukocytes, dampening "classic" IL-6 signaling (which is anti-inflammatory and regenerative in many tissues). Concurrently, the elevated pool of sIL-6R binds circulating IL-6, forming complexes that can activate cells lacking mIL-6R via gp130—a process known as "trans-signaling."
• Quantile-dependent CRP responses: The genetic impact of CRP rs1205 is quantile-dependent. While it slightly alters baseline levels, its effect is dramatically amplified during active inflammatory challenges (such as major surgery, severe infection, or active autoimmune disease), leading to more pronounced spikes or blunted plateaus depending on the genotype.
• Feedback loop: Circulating CRP itself can act as a physiological activator of ADAM-mediated IL-6R shedding, establishing a complex feedback loop that modulates trans-signaling and limits localized tissue inflammation.

[Inflammatory Stimulus] 
       │
       ▼
[IL-6 Release]
       │
       ├─► Classic Signaling (via mIL-6R) ──► Hepatocyte CRP Production (rs1205 modifies CRP output)
       │
       └─► Trans-Signaling (via sIL-6R) ◄── [IL6R rs2228145 increases shedding of mIL-6R to sIL-6R]

Clinical implications and considerations

• Confounding disease markers: Because rs1205 and rs2228145 directly alter baseline and peak CRP levels, clinical assessments of systemic inflammation (e.g., using hs-CRP to grade cardiovascular risk or monitor autoimmune flare-ups) can be genetically confounded. A lower CRP reading in a patient with rs1205 or rs2228145 variants may not represent lower disease activity, but rather a genetically blunted acute-phase response.
• Therapeutic targets: The biological mechanism of the IL6R rs2228145 variant closely mimics the therapeutic effects of IL-6 receptor antagonists (such as tocilizumab). Understanding an individual's genotype can provide insights into their baseline IL-6 signaling trajectory and potential responsiveness to anti-inflammatory therapies.

Bottom line

The CRP rs1205 and IL6R rs2228145 variants are scientifically validated modifiers of systemic inflammation. While rs1205 directly limits or amplifies the physical synthesis of C-reactive protein during acute-phase responses, rs2228145 fundamentally rewires IL-6 signaling by promoting receptor shedding, shifting the body from classic localized signaling to systemic trans-signaling and altering downstream CRP release.